

CARB-X Antibacterial Treatment and Prevention Product Portfolio 2019.05.21

Sponsor	Product	Novelty			Description	Priority		Development Stage			
		New Abx Class	New	New Target		CDC	WHO	Hit to Lead	Lead Optimization	Pre-Clinical	Phase I
			Non-traditional Product								
Amicrobe	Amicidin-β		✓		Next-generation local antimicrobial	✓	✓			Broad spectrum	
Antabio	PEI		✓	✓	Pseudomonas elastase inhibitor	✓	✓		P. aeruginosa		
Bugworks Research	GYROX	✓			Gyrase-topoisomerase inhibitor	✓	✓		Gram-negative activity		
ContraFect	Gram-negative amurins	✓			Phage-encoded lytic therapeutic	✓	✓	Gram-negative activity			
ContraFect	Gram-negative lysins		✓	✓	Recombinant lysin protein	✓	✓	P. aeruginosa			
Debiopharm International SA	Debio1453	✓		✓	Narrow-spectrum inhibitors of FabI	✓	✓		Neisseria Gonorrhoeae		
Debiopharm International SA	Debio1454	✓		✓	Narrow-spectrum inhibitors of FabI	✓	✓		Acinetobacter baumannii		
Entasis Therapeutics	ETX0282CPD P				Oral Gram-negative combination	✓	✓			Gram-negative activity	
Entasis Therapeutics	Non-BL PBPI	✓			Non-beta-lactam PBPI	✓	✓		Gram-negative activity		
Forge Therapeutics	FG-LpxC-LUNG	✓		✓	LpxC inhibitor	✓	✓		Gram-negative activity		
Forge Therapeutics	FG-LpxC-UTI	✓		✓	LpxC inhibitor	✓	✓		Gram-negative activity		
Idorsia	TopESKAPE	✓			Dual-acting topoisomerase inhibitor	✓	✓		Acinetobacter, Pseudomonas, & Enterobacteriaceae		
Inhibrx	INBRX-111		✓	✓	Multi-specific antibody	✓	✓			P. aeruginosa	
Integrated BioTherapeutics	IBT-V02		✓		Multi-valent toxoid vaccine	✓	✓			S. aureus	
Macrolide	Novel Macrolides				Novel macrolide antibiotics with Gram-negative activity	✓	✓		Gram-negative activity		
Microbiotix	T3SS Inhibitor		✓	✓	Virulence modifier	✓	✓	P. aeruginosa			
MicRx	MRX-8				Soft drug polymyxin	✓	✓			Gram-negative activity	
Polyphor	OMPTA POL7306	✓		✓	Novel class, MDR/XDR ESKAPE	✓	✓			Gram-negative activity	
SciBac	SCB-102		✓		Microbiome	✓	✓		C.difficile		
Seres Therapeutics	SER-155		✓		Microbiome - transplant patients	✓	✓	Broad spectrum activity vs CRE/VRE			
Summit Therapeutics	SMT-571 Series	✓		✓	Novel class, orally active antibiotic	✓	✓		Neisseria Gonorrhoeae		
Tetraphase Pharmaceuticals	TP-6076				Next-generation tetracycline	✓	✓				Acinetobacter & Enterobacteriaceae
VenatoRx	VNRX-PBP	✓			β-lactamase resistant PBP inhibitor	✓	✓	Enterobacteriaceae			

CARB-X Antibacterial Devices and Diagnostic Product Portfolio

Sponsor	Type	Technology	Description			
			Feasibility Demonstration	Optimization and Preparation for Development	Product Development	System Integration and Testing
Helixbind	Hospital Dx	Automated culture-free pathogen ID			Bloodstream Infections	
Proteus	Rapid POC Dx	Optical bacterial imaging		POC Diagnostic		
Specific Diagnostics	Hospital Dx	Colorimetric Sensor Array to detect VOCs			Bloodstream Infections	
Talis	Point of care Dx	Pathogen ID, Phenotypic AST	AST Neisseria gonorrhoeae, NID NG and Chlamydia trachomatis			
T2 Biosystems	Hospital Dx	Expanded bacteria and resistance panels for T2Dx		Bloodstream infections		

The above projects are Powered by CARB-X utilizing non-dilutive funding from BARDA, Wellcome Trust, Germany's Federal Ministry of Education and Research (BMBF), and NIAID, with some funding for specific projects from the UK Government's Global Antimicrobial Resistance Innovation Fund (UK GAMRIF and the Bill & Melinda Gates Foundation). Characterizations of new Abx Class and New Target by CARB-X, following Pew pipeline analysis: <http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics-currently-in-clinical-development>. Other characterizations by CARB-X experts and external expert opinion. Abx = traditional small molecule antibiotic. Non-traditional Product = not a traditional small molecule antibiotic.